Why Twist Bioscience Corporation (TWST) Stock Fell 18.6% on Oct 6, 2026
The clearest new catalyst: Violent momentum reversal / profit-taking (no fresh company news).
Why did TWST stock fall?
Twist Bioscience fell 18.55% to $166.97 on Tuesday, October 6, 2026 (from $205.00), a violent momentum reversal after nearly doubling from its June 30 close of $102.88 (it hit a 52-week intraday high of $219.71 that morning before reversing). There was no new adverse company catalyst; heavy profit-taking coincided with a broad pullback in high-momentum genomics/testing stocks (10x Genomics -17.5%) and with disclosure that ARK Invest had sold another ~90,713 shares on October 5 — reportedly its 21st straight session of selling — while recent insider sales added to the supply overhang.
- Violent momentum reversal / profit-taking (no fresh company news): TWST had run from a June 30 close of $102.88 to $205.00 by October 5 (nearly +99%) and printed a new 52-week intraday high of $219.71 early October 6 before collapsing to close down 18.55% on roughly 8.6 million shares. No scientific, regulatory, reimbursement or company-news shock landed that day — the move was a sharp unwind of an extended rally.
- Broad genomics/testing selloff: The reversal was not isolated: other high-flying genomics names sold off hard the same day, with 10x Genomics down about 17.5% and the ARK Genomic ETF (ARKG) off roughly 9%. Because TWST and 10x Genomics were large ARKG holdings, the ETF's drop was partly a result of their declines rather than an independent catalyst; contemporaneous coverage characterized the group's fall as profit-taking after an extraordinary run.
- ARK distribution and recent insider selling (supply overhang): ARK Invest's published trades showed sales of about 90,713 TWST shares on October 5 (~$17.1 million), described in October 6 coverage as its 21st consecutive session of selling and explicitly linked to the reversal. Separately, CEO Emily Leproust's Form 4 (filed October 5) reported 46,391 shares sold October 1-2 (~$8.77 million) under a pre-existing Rule 10b5-1 plan — recent, pre-planned selling that added to the supply overhang rather than a new October 6 event.
How the story developed
- June 30, 2026TWST closes at $102.88 (the base of the rally).
- October 5, 2026TWST closes at $205.00 (nearly +99% since June 30); ARK sells another ~90,713 shares (reportedly its 21st straight session).
- October 6, 2026TWST prints a 52-week intraday high of $219.71, then reverses to close -18.55% at $166.97 as genomics high-flyers sell off.
What it could mean for TWST investors
The constructive case
- The decline was profit-taking and flow-driven, not a response to any deterioration in Twist's business.
- Even after the drop, TWST remains well above its mid-year levels, reflecting the strength of the prior run.
The cautious case & what could invalidate it
- Persistent ARK distribution and recent insider selling are a continuing supply overhang.
- A name that nearly doubled in a quarter is richly valued and prone to violent reversals.
- A broad de-rating of the genomics momentum trade could keep pressure on the whole group.
Initial detection
BestStocks first flagged TWST intraday on Oct 6, 2026; this analysis was finalized after the close using the confirmed −20.3% session move and additional catalyst research.
Show the initial intraday note
Twist Bioscience Corporation (TWST) fell 18.55% to close at $166.97 on Tuesday, October 6, 2026 (from $205.00), in a violent momentum reversal after nearly doubling from its June 30 level — the stock even printed a fresh 52-week intraday high of $219.71 early in the session before collapsing. There was no new adverse company news; the drop was heavy profit-taking, alongside a broad pullback in high-flying genomics/testing names (10x Genomics fell about 17.5%), amplified by disclosure that ARK Invest had sold another ~90,713 shares (reportedly its 21st straight session of selling) and by recent insider sales.
What to watch next: This was a positioning/flow unwind, not a fundamental break, so the key questions are whether ARK's persistent selling continues and whether the whole genomics momentum trade keeps de-rating. Watch for any actual operating news (orders, NGS/synthetic-biology demand, margins) at Twist's next update, and note that the stock remains far above where it started the summer. A name that nearly doubled in a quarter can stay volatile in both directions.
Other developments that session
TWST stock fell 9.7% after an insider sold 1.7 million shares during Tuesday trading.
Frequently asked questions
Why did Twist Bioscience Corporation (TWST) stock fall on Oct 6, 2026?
Twist Bioscience fell 18.55% to $166.97 on Tuesday, October 6, 2026 (from $205.00), a violent momentum reversal after nearly doubling from its June 30 close of $102.88 (it hit a 52-week intraday high of $219.71 that morning before reversing). There was no new adverse company catalyst; heavy profit-taking coincided with a broad pullback in high-momentum genomics/testing stocks (10x Genomics -17.5%) and with disclosure that ARK Invest had sold another ~90,713 shares on October 5 — reportedly its 21st straight session of selling — while recent insider sales added to the supply overhang.
How much did TWST stock fall on Oct 6, 2026?
TWST fell 20.3% during the Oct 6, 2026 trading session.
What were the main drivers behind TWST's move?
Violent momentum reversal / profit-taking (no fresh company news); Broad genomics/testing selloff; ARK distribution and recent insider selling (supply overhang).